Rapid Communication

You have full text access to this OnlineOpen article

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study

  1. Olav Dalgard1,†,*,
  2. Kristian Bjøro2,
  3. Kjell Block Hellum3,
  4. Bjørn Myrvang4,
  5. Ståle Ritland5,
  6. Kjell Skaug6,
  7. Nils Raknerud7,
  8. Helge Bell1

Article first published online: 22 NOV 2004

DOI: 10.1002/hep.20467

Issue

Hepatology

Hepatology

Volume 40, Issue 6, pages 1260–1265, December 2004

Additional Information

How to Cite

Dalgard, O., Bjøro, K., Hellum, K. B., Myrvang, B., Ritland, S., Skaug, K., Raknerud, N. and Bell, H. (2004), Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology, 40: 1260–1265. doi: 10.1002/hep.20467

Author Information

  1. 1

    Department of Medicine, Aker University Hospital, Oslo, Norway

  2. 2

    Rikshospitalet, Oslo, Norway

  3. 3

    Akershus University Hospital, Oslo, Norway

  4. 4

    Ullevål University Hospital, Oslo, Norway

  5. 5

    Buskerud Hospital, Drammen, Norway

  6. 6

    National Institute of Public Health, Oslo, Norway

  7. 7

    Department of Pathology, Aker University Hospital, Oslo, Norway

  1. †

    fax: (38) 47 22 11 91 81

*Medical Department, Aker University Hospital, Oslo 0514

Publication History

  1. Issue published online: 24 NOV 2004
  2. Article first published online: 22 NOV 2004
  3. Manuscript Accepted: 19 AUG 2004
  4. Manuscript Received: 21 MAY 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (121K)

References

  • 1
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
  • 2
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
  • 3
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.
  • 4
    Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38–47.
  • 5
    Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003; 98: 2354–2362.
    Direct Link:
  • 6
    Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. HEPATOLOGY 1994; 19: 1321–1324.
    Direct Link:
  • 7
    Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993–999.
  • 8
    Bjoro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002; 37: 226–232.
  • 9
    Nousbaum JB, Cadranel JF, Savary O, Legrand MC, Dumouchel P, Gouâerou H. Sustained virological response after a short course of treatment with interferon and ribavirin in two chronic hepatitis C patients. J Hepatol 2003; 39: 655–656.
  • 10
    Lee WM, Reddy KR, Tong MJ, Black M, van Leeuwen DJ, Hollinger FB, et al. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. HEPATOLOGY 1998; 28: 1411–1415.
    Direct Link:
  • 11
    Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. HEPATOLOGY 2001; 33: 419–423.
    Direct Link:
  • 12
    Dermer J, Lagier R, Flynn J, Zayati C, Kolberg J, Collins M, et al. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol 1996; 34: 901–907.
  • 13
    Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34: 2259–2266.
  • 14
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981; 1: 431–435.
    Direct Link:
  • 15
    Ide T, Kumashiro R, Hino T, Murashima S, Ogata K, Koga Y, et al. Short term and two-step interferon therapy for chronic hepatitis C patients with low HCV RNA levels. Hepatol Res 2002; 22: 145–151.
  • 16
    Nomura H, Tsuchiya Y, Maruyama T, Miki K, Yokota T, Okubo H. The effects of a high dose, short course of interferon on hepatitis C. J Gastroenterol Hepatol 1999; 14: 85–89.
    Direct Link:
  • 17
    Zeuzem S. Clinical implications of hepatitis C viral kinetics. J Hepatol 1999; 31( Suppl 1): 61–64.
  • 18
    Sanchez-Tapias JM, Diago M, Escartin P, Enriques J, Moreno R, Ramero-Gomez M, et al. Longer treatment duration with Peginterferon alfa-2a (40 KD) and Ribavirin in naïve patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: preliminary results of the TeraViC-4 study. HEPATOLOGY 2003; 38( Suppl 1): 306A.
View Full Article (HTML) Get PDF (121K)